PROSERA Phase 3 Shows Clinical Benefit in PAH; Gossamer Bio Targets September NDA Filing
GOSS sits 32% above its 52-week low of $0.163 on elevated volume (3.5× avg).
Summary
Gossamer Bio announced positive Phase 3 results for its drug candidate seralutinib (PROSERA) in pulmonary arterial hypertension (PAH), with plans to file a New Drug Application (NDA) in September 2026. This significant product development news provides a crucial positive catalyst for the company, which has recently faced severe financial distress, including a reiterated going concern warning and a Nasdaq delisting notice. Additionally, the company secured voting agreements from supporting noteholders for its recently announced distressed debt exchange, a positive step towards completing the restructuring. While the headline also mentioned a Q1 net loss of $46.7 million, this information was previously reported on May 15. The positive clinical data for PROSERA offers a potential path to future revenue and validates a key asset, which is highly material for a company of Gossamer Bio's size and current financial situation. Investors will now closely watch the NDA filing process and the successful completion of the debt exchange.
At the time of this announcement, GOSS was trading at $0.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $45.2M. The 52-week trading range was $0.16 to $3.87. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.